When Velocity Clinical Research launched in December 2017, it had just two sites. Owned sites (SMOs) were the prevalent model at the time, and site networks were a collection of independent sites with a single point of contact. Velocity offered an alternative – a wholly owned and fully integrated network of clinical trial sites. That … Read more
Paul Evans was featured in Applied Clinical Trials‘ latest article weighing in on the real-world implications of recent executive orders affecting DEI initiatives nationwide. In the piece, Paul underscores Velocity’s unwavering commitment to inclusive, patient-centered research environments, stating: “Velocity believes that clinical trials should be a safe space for the entire LGBT community… It’s important … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of a new article reporting on a study that found prolonged elevation of hepatic biomarkers and fibrosis (scarring) scores is associated with a greater risk of negative clinical outcomes in patients with primary biliary cholangitis (PBC). PBC is a rare liver disease that can … Read more
Velocity is collaborating with Merck to enhance the way trial insights are shared within Merck and across Velocity sites worldwide. Through fast-response data exchange, we’ve developed the Velocity Insight Platform (VIP), a dynamic dashboard that provides actionable metrics to optimize site activities. A huge thank you to the data team at Merck for their dedication … Read more
Nadege Gunn, MD, CPI, DABOM, FAASLD, has been named a Fellow of the American Association for the Study of Liver Diseases (AASLD)! This designation is the highest honor awarded to AASLD members and recognizes Dr. Gunn’s exceptional contributions to liver disease research and clinical care. In addition to her impact on the broader research community, … Read more
Clinical trials have been steadily leaving the UK for years. In 2021, just 2.2% of patients recruited to global trials were from the UK. By contrast, France, which has a similar population size, accounted for 3.9% that year. That’s not to say we don’t still have some clout (the UK ranks fourth globally for Phase … Read more
Charles Eger, MD, contributed to new research on a combination vaccine intended to provide protection against both seasonal flu and COVID-19 in a single shot. Early results from the Phase 1/2 trial show that the vaccine is well-tolerated and induces strong immune responses, potentially paving the way for a more convenient approach to respiratory virus … Read more
Luke Boylan, MBChB, MBA, Principal Investigator at Velocity in North London, recently attended the Parexel Site Alliance Network event. This collaborative gathering included NHS/NIHR-affiliated sites and other commercial research organizations, providing an invaluable opportunity to discuss the evolving landscape of clinical trials in the U.K. Dr. Boylan’s key takeaways from the event: Regulatory Improvements: There … Read more
Paul Evans sat down with Patricia Leuchten on the Leaders & Legends podcast, where they discussed the state of research sites and the broader industry. Listen now to hear Paul’s thoughts on: The evolution of clinical research sites and what’s ahead for the industry. Challenges in patient recruitment and the role of site-based technology. His … Read more
Women’s health remains one of the most overlooked and underrepresented areas in clinical research, often leading to gaps in treatment and understanding. Similar to obesity research, disorders relating to reproductive health include symptoms that are highly stigmatized and patients can be reluctant to seek treatment or join clinical trials. This is why Velocity set up … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.